The value of specifying brand-name antiepileptic drugs

Archives of Neurology

Volumn 66, Issue 11, 2009, Pages 1415-1416

  Ng, Yu Tze ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; GENERIC DRUG; LAMOTRIGINE; ZONISAMIDE;

AREA UNDER THE CURVE; BIOEQUIVALENCE; COMORBIDITY; DRESS SYNDROME; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MEGADOSE; DRUG TOLERABILITY; EPILEPSY; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; SEIZURE; SHORT SURVEY;

ANTICONVULSANTS; DRUGS, GENERIC; EPILEPSY; HUMANS; THERAPEUTIC EQUIVALENCY;

EID: 70449638248     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.232     Document Type: Short Survey

References (16)

1. Heaney DC, Sander JW. Antiepileptic drugs: generic versus branded treatments. Lancet Neurol. 2007;6(5):465-468. (Pubitemid 46551869)
2. Crawford P, Feely M, Guberman A, Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? a review of issues. Seizure. 2006;15(3):165-176.
3. Bialer M. Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia. 2007;48(10): 1825-1832. (Pubitemid 47537455)
4. Shaw SJ, Krauss GL. Generic antiepileptic drugs. Curr Treat Options Neurol. 2008;10(4):260-268.
5. Berg MJ. What's the problem with generic antiepileptic drugs? Neurology. 2007;68(16):1245-1246.
6. LeLorier J, Duh MS, Paradis PE, et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology. 2008;70(22, pt 2):2179-2186.
7. Burkhardt RT, Leppik IE, Blesi K, Scott S, Gapany SR, Cloyd JC. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology. 2004;63(8):1494-1496. (Pubitemid 39426288)
8. Berg MJ, Gross RA, Haskins LS, Zingaro WM, Tomaszewski KJ. Generic substitution in the treatment of epilepsy: patient and physician perceptions. Epilepsy Behav. 2008;13(4):693-699.
9. Liow K, Barkley GL, Pollard JR, Harden CL, Bazil CW; American Academy of Neurology. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology. 2007; 68(16):1249-1250.
10. Feely M, Crawford P, Kramer G, Guberman A. Risk management in epilepsy: generic substitution and continuity of supply. Eur J Hosp Pharm Sci. 2005;11:83-87.
11. Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia. 2007; 48(3):464-469. (Pubitemid 46365174)
12. Sabroe TP, Sabers A. Progressive anticonvulsant hypersensitivity syndrome associated with change of drug product. Acta Neurol Scand. 2008; 117(6):428-431. (Pubitemid 351643676)
13. Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux PY. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine. Dis Manag. 2007;10(4):216-225. (Pubitemid 47403497)
14. LeLorier J, Duh MS, Paradis PE, et al. Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. Curr Med Res Opin. 2008;24(4): 1069-1081. (Pubitemid 351579165)
15. Behncken S. Strategic plan to accelerate Australian drug development. http://www.medicalnewstoday. com/articles/33913.php. Published November 22, 2005; Accessed July 17, 2008.
16. Malkovic T. WA and Australia missing out on drug R&D opportunities. http://sciencewa.net.au/index .php?option=com-content&view=article&id= 2174: wa-and-australia-missing-out-on-drug-radopportunities& catid=180:News&Itemid=200075. Published June 17, 2008. Accessed July 17, 2008.